Podcasts about mounjaro

On this episode of Diabetes Connections In the news… The FDA approves a new indication and health benefit for Mounjaro, lots of CGM news including an update on Medicare coverage for people who don't use insulin and a new study about using CGM when you don't have diabetes, metformin and aging, statins and type 2, and did you know there was a Dolly Parton diabetes connections? That and much more... Check out all of our events like Moms' Night Out and Club 1921 here. Announcing Community Commericals! Learn how to get your message on the show here. Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Omnipod - Simplify Life All about Dexcom  All about VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  On this episode of Diabetes Connections In the news… The FDA approves a new indication and health benefit for Mounjaro, lots of CGM news including an update on Medicare coverage for people who don't use insulin and a new study about using CGM when you don't have diabetes, metformin and aging, statins and type 2, and did you know there was a Dolly Parton diabetes connections? That and much more.. that's coming up right after this. (AD BREAK) Welcome! I'm your host Stacey Simms and this is an In The News episode.. where we bring you the top diabetes stories and headlines happening now. A reminder that you can find the sources and links and a transcript and more info for every story mentioned here in the show notes. Welcome to September! Want to let you know about a webinar I'm doing with Abbott later this month. That's Sept 23 at 7pm ET. We'll be talking about ketones, DKA and learn more about their dual CGM/ketone monitor that was just approved – more on that coming up. But please register – the link is in the show notes. So much going on over here – tomorrow night we have our Club 1921 in Charlotte, later this month Moms' Night Out Detroit/Bloomfield and in October we're going to Seattle. Please join us. More at d-c dot com slash events. Okay.. our top story this week: XX Another indication for Mounjaro – the FDA approved it to lower the risk of major adverse cardiovascular (CV) events (MACE), including CV death, non-fatal heart attack, or non-fatal stroke in adults with type 2 diabetes who are at high risk for these events. Mounjaro – the brand name of tirzepatide - is already approved as an adjunct to diet and exercise to improve blood sugar in adults and children 10 years of age and older with type 2 diabetes. The approval was based on results from the largest and longest tirzepatide study to date, enrolling more than 13,000 participants across 30 countries over more than four and a half years. In the trial, Mounjaro demonstrated non-inferiority to Trulicity (dulaglutide), a GLP-1 treatment with established cardiovascular benefit, with an 8% lower rate of cardiovascular death, heart attack or stroke (MACE-3). The estimated hazard ratio for time to first MACE was 0.92 (95.3% CI: 0.83, 1.01) for Mounjaro compared to Trulicity (dulaglutide). https://www.prnewswire.com/news-releases/fda-approves-lillys-mounjaro-tirzepatide-to-reduce-cardiovascular-risk-in-adults-with-type-2-diabetes-302862415.html XX The FDA approves the Libre Duo – the first device designed to continuously monitor both blood sugar levels and ketone levels in people with diabetes. The Libre Duo 10-Day Continuous Dual Glucose Ketone Monitoring System is now approved for those ages 2 and older. Until now, the agency said, people had to monitor ketone levels with separate tests that only provided a single measurement at one point in time. The new system combines blood sugar and ketone tests and monitors them continuously. Readings -- and alerts in case of dangerous trends -- are sent wirelessly to a smartphone app. The FDA previously granted "breakthrough device" status to the system, which is meant to expedite the device's development and review. https://www.upi.com/Top_News/US/2026/08/25/fda-oks-blood-sugar-ketone-monitor/5521787688375/ XX Diabetes tech firms Dexcom and Abbott are watching closely for a Medicare coverage expansion that could significantly broaden access to their glucose sensors. The Centers for Medicare and Medicaid Services is expected to expand Medicare coverage of continuous glucose monitors to people with diabetes who do not take insulin. Currently, coverage is limited to people with Type 1 or Type 2 diabetes who take insulin or have a history of problematic low blood sugar. Dexcom CEO Jake Leach told investors in a late July earnings call that the company expects to hear back from the CMS before the end of the year, with coverage going into effect in mid-2027.     Dexcom presented results of a randomized, controlled trial earlier this summer at the American Diabetes Association's Scientific Sessions that it expects will support the CMS' decision. The 26-week study found that people who used a CGM had a larger hemoglobin A1C reduction than the control group and spent five more hours per day in a normal glucose range than the control group. https://www.medtechdive.com/news/dexcom-abbott-await-medicare-coverage-expansion-for-cgms/828775/ XX A new study suggests continuous glucose monitors (CGMs) may offer benefits for people with type 1 diabetes that go beyond improving blood sugar and reducing hypoglycemia.   Researchers analyzed health records from more than 8,400 adults with type 1 diabetes receiving care through the Veterans Health Administration. Over one to four years of follow-up, people who started using a CGM had a 10% to 16% lower risk of death from any cause compared with those who did not use one.   The association appeared strongest among people over age 65 and those who were not using insulin pumps. Researchers did not find meaningful differences based on A1C, race or ethnicity, or frailty.   Importantly, this was an observational study using medical records, not a randomized clinical trial, so it cannot prove that CGM use directly caused the lower death rate. But the findings suggest CGM may have important long-term health benefits beyond glucose management.https://visualize.jove.com/42319755-continuous-glucose-monitoring-initiation-is-associated-with-reduced-mortality-in-older-onset-type-1-diabetes-patients-a-target-trial-emulation-study-within-the-veterans-health-administration XX We've been talking about people without diabetes using CGMs for a long time.. now a new study weighs in. Research published in JAMA finds that this wellness trend isn't helpful for people without a diabetes diagnosis. They found that the strongest evidence for CGM use is for people who are already living with diabetes, but not for those without the condition who use them for wellness purposes. It's also worth noting, though, that this new study is a narrative review. This means that the researchers drew their conclusions from the findings reported in several other studies. More randomized controlled trials would be necessary to see whether there are any meaningful health benefits of using a CGM if you don't have diabetes.   Dower also warned that constantly monitoring your blood sugar when you don't have diabetes could lead to unintended health anxiety. In some cases, you may even make accidental lifestyle changes that could be harmful. "[Blood sugar] spikes may occur after meals, but if this leads someone to replace healthy food such as fruit with unhealthy food such as something high in fat but low in carbohydrate, the glucose information has done more harm than good," Dower said. https://www.verywellhealth.com/blood-sugar-monitor-for-people-without-diabetes-12058575   XX   Could metformin somehow influence the biological processes that drive aging? A new review found evidence that metformin may affect several key features of aging, including how cells use energy, inflammation, cellular damage and even some changes in gene activity. Animal studies have shown longer lifespans or improvements in markers of biological aging, while some human studies have also found promising results.   But researchers say there's still no proof that metformin actually slows aging or helps healthy people live longer. Most human research has involved people with diabetes or other health conditions, and one large trial found that while metformin helped prevent type 2 diabetes, it did not reduce cancer, cardiovascular disease or deaths.   Researchers say larger clinical trials in people without diabetes are needed to determine whether metformin can truly extend healthy lifespan—or whether its benefits are primarily related to preventing and treating specific diseases. https://www.technologynetworks.com/drug-discovery/news/metformin-may-influence-longevity-through-the-gut-microbiome-and-epigenetic-changes-416035 XX More to come including more research on a spice thought to help diabetes, predictions about the number of people who may be living with type 1 in the years to come around the world, and a connection I didn't know about between diabetes and Dolly Parton.   XX A compound found in turmeric may help protect blood vessels from some of the damage caused by Type 1 diabetes. In rats, curcumin reduced inflammation, improved cellular signaling, and restored vascular health to levels resembling those of nondiabetic animals. The results hint at a possible new way to reduce the long-term cardiovascular risks of diabetes, but human trials are still needed. Curcumin, the natural compound responsible for turmeric's vivid yellow color, is widely studied for its anti-inflammatory and antioxidant properties. https://www.sciencedaily.com/releases/2026/08/260824065543.htm XX New research estimates the number of people living with type 1 diabetes (T1D) worldwide will increase by 29% from 9.4 million in 2025 to 12.1 million in 2049. This will be presented at EASD, the Annual Meeting of The European Association for the Study of Diabetes (EASD) in Milan, Italy (Sept 28 – Oct 2 The USA will see an increase of over half a million, going from 1,492,825 to 2,055,235. The authors suggest that the reasons for the predicted high incidence and prevalence in 2049 in countries such as Australia, US, UK are likely to be a combination of genetics, environmental triggers and also high case detection rates (due to the good health care infrastructure here and in other HIC). Unlike previous estimates, the DIAMOND-T1D model takes historical patterns of insulin availability into account and aims to provide global, regional and country-specific estimates of T1D incidence, prevalence and mortality from 1900 to 2050. Although the majority of people with T1D live in high-income countries (HIC) and middle-income countries (MIC), the largest relative increase in the T1D prevalence is expected to occur in LIC as access to insulin, glucose monitoring and survival all improve in those countries. https://www.news-medical.net/news/20260828/Type-1-diabetes-cases-projected-to-increase-worldwide-by-2049.aspx XX Early initiation of statins after a diagnosis of type 2 diabetes was associated with a lower risk of dementia, according to a study published in The Lancet Regional Health – Europe. According to the Lancet Commission, nearly half of dementia cases could theoretically be prevented by eliminating 14 risk factors. "Detecting and treating high levels of low-density lipoprotein cholesterol (LDL-C) from midlife is one such highlighted risk factor," From Danish registers, researchers identified 132,585 statin-naive individuals who developed type 2 diabetes from 2006 through 2019, with follow-up until the end of 2021.   Medical records were searched for diagnoses of all-cause dementia. A clone-censor-weight design was used to analyze dementia incidence in patients with no statin initiation within five years after diagnosis, in those with early statin initiation within one year and in those with late statin initiation between one and five years after diagnosis.   https://medicalxpress.com/news/2026-08-early-statins-diagnosis-diabetes-dementia.html   XX We are heartbroken over the loss of our friend Dolly Parton. Dolly was a beloved icon whose extraordinary generosity, warmth, and compassion touched countless lives, including those of the Children's Diabetes Foundation and the Barbara Davis Center for Diabetes. Her support of The Carousel Ball and Carousel of Hope Ball reflected her deep commitment to helping children and families affected by type 1 diabetes. Beyond her remarkable talent, Dolly will be remembered for the kindness and joy she shared so generously with others. Our hearts are with her family, friends, and all who loved her as we celebrate her extraordinary life and lasting legacy. She will be deeply missed.    

GLP-1 medications like Ozempic, Wegovy, Zepbound, and Mounjaro have reshaped the weight-loss landscape almost overnight — but the way they're often prescribed leaves people under-fueled, losing muscle, and going it alone. In this episode of The Coaching Lab, host Leigh Baker sits down with National Board Certified Health & Wellness Coach Erin Chain and triple-board-certified physician Dr. Sheri Poznanovic of Optin Health & Nutrition to unpack what's really happening in the GLP-1 era — and where health and wellness coaching fits into the care plan.Together they explore why so many people on GLP-1s aren't eating or hydrating enough, how rapid weight loss can mask dangerous muscle mass loss, and why a "prescribe-and-disappear" model falls short. Dr. Poznanovic explains the multidisciplinary approach the Obesity Medicine Association recommends — combining medication, nutrition, body composition testing, VO2 max assessment, and coaching — while Erin shares real-world stories of clients navigating low energy, food noise, protein gaps, medication interactions, and the stigma of being on a GLP-1.Whether you're a coach, a clinician, an employer weighing GLP-1 coverage, or someone considering these medications yourself, this conversation offers a grounded, human look at doing weight loss in a way that protects strength, health span, and quality of life — not just the number on the scale.In this episode: • Why coaching alongside a GLP-1 changes outcomes • The under-eating and muscle-loss risks no one warns you about • Protein targets, carbs, and why "anti-carb" advice backfires • Body composition and VO2 max testing in weight management • Medication interactions as you lose weight • Navigating stigma and the joy of food • What employers and coaches should know before adding GLP-1sCoaches: Explore CE credits at catalystcoachinginstitute.com Employers: Learn about Catalyst Coaching's GLP-Whole offering — results@catalystcoaching360.com Join us this fall at the Rocky Mountain Coaching Retreat & Symposium: catalystcoachinginstitute.com/retreatInfo re earning your health & wellness coaching certification, annual Rocky Mountain Coaching Retreat & Symposium & more via https://www.catalystcoachinginstitute.com/ Best-in-class coaching for Employers, EAPs & wellness providers https://catalystcoaching360.com/Tap into the home of the (freely available) Not Done Yet! articles on unlocking life's 2nd half here.YouTube Coaching Channel https://www.youtube.com/c/CoachingChannelContact us: Results@CatalystCoaching360.comTwitter: @Catalyst2ThriveWebsite: CatalystCoaching360.comIf you are a current or future health & wellness coach, please check out our Health & Wellness Coaching Community on Facebook: https://www.facebook.com/groups/278207545599218.  This is a wonderful group if you are looking for encouragement, ideas, resources and more. 

Is gaining weight really the worst thing that can happen?Obviously, there are a million worse things. But for me, the answer is still kind of yes—and not because of the number on the scale.At my highest weight, the biggest loss wasn't clothing size or how I looked. It was my quality of life. My anxiety got worse. I dealt with agoraphobia and depression. I avoided things, sat on the sidelines, and slowly made my world smaller.After gaining a few pounds back this summer, I had a wake-up call. I'm nowhere near where I was, but I also know I never want to go back to living that way.This episode is about what weight gain can quietly take from you—and why I'm choosing to stop that slide now.Irresistible Links:Show Notes

You cannot open your phone anymore without hearing about Ozempic, Wegovy, Mounjaro, Zepbound, retatrutide, and before-and-after transformations. One person says GLP-1s are the greatest thing ever. Another says they are going to destroy your health. As usual, the truth is somewhere in the middle. In this episode, I break down GLP-1s specifically through the lens of perimenopause and menopause, because midlife women are dealing with a completely different metabolic landscape. Estrogen is changing. Muscle is easier to lose. Insulin sensitivity may be shifting. Sleep is falling apart. Belly fat is showing up where it never used to. And simply telling a woman to eat less and exercise more is not a strategy. We talk about where GLP-1s can be incredibly useful, why HRT and GLP-1s are not interchangeable, and why protecting muscle has to be one of your top priorities if you are using these medications. I also get into dosing, microdosing, appetite suppression, thyroid and hormone optimization, realistic weight-loss rates, and why the goal should never be to get as skinny as possible as fast as possible. The goal is to lose fat while preserving muscle, supporting hormones, improving metabolic health, and having an actual plan for what happens after the weight comes off. In this episode, we cover: Why menopause changes fat distribution and increases abdominal fat for many women How declining estrogen, muscle loss, sleep, and insulin resistance affect midlife weight How GLP-1 medications work beyond simple appetite suppression Why GLP-1s are not "cheating" Why GLP-1 therapy does not replace HRT Whether HRT and GLP-1s can be used together Why muscle loss is one of the biggest concerns with GLP-1 use Why protein and resistance training matter so much Why having no appetite does not mean your dose is perfect Microdosing versus standard GLP-1 dosing Why increasing your dose too quickly can backfire What a realistic rate of weight loss can look like The importance of thyroid and hormone optimization when weight loss stalls Why maintenance needs to be part of the plan from day one Who This Episode Is For This episode is for women in perimenopause and menopause who are considering a GLP-1, already taking one, or wondering whether these medications could help with stubborn midlife weight gain. It is especially for women who want to lose fat without sacrificing muscle, energy, hormones, bone health, or long-term metabolic health. If you are confused by the microdosing hype, worried about muscle loss, unsure whether you should do HRT or a GLP-1 first, or wondering why your weight loss has stalled even though you are taking medication, this episode is for you.     Sponsors BEAM: Use coupon code HORMONE for 20% off your order Try the power of copper peptides on your skin today and get 20% off your order with coupon code km20 here.     Are you in perimenopause or postmenopause and struggling with symptoms—but not getting the support you deserve? At Midlife Solutions, we specialize in hormone optimization for women in midlife. Our all-female clinical team offers telehealth care across all 50 U.S. states, with the ability to prescribe bioidentical estrogen, progesterone, testosterone, and thyroid medication.   Book your FREE Hormone Discovery Call Find out what's really driving your symptoms and what your next best steps are.   Visit the website: https://karenmartel.com   Shop the Midlife Solutions Store Over-the-counter bioidentical hormone creams and oils — no prescription needed. Including: • Progesterone • Estrogen Face Cream • Vaginal Moisturizer and more!   Take the Hormone Quiz Discover hidden hormone imbalances that could be driving your symptoms. Get personalized results (and yes, they may surprise you).   Women's Peptide Weight Loss Program Clinically guided, hormone-aware weight loss for midlife women.   Midlife RESET HRT Program A complete, supportive approach to hormone replacement therapy in midlife.   Your host: Karen Martel Certified Hormone Specialist, Transformational Nutrition Coach, & Weight Loss Expert   Karen's Facebook Karen's Instagram

PODCAST LAS NOTICIAS CON CALLE 28 de agosto de 2026 - EEUU negocia quedarse con una tajada "masiva" del petróleo de Venezuela, Venezuela negocia quedarse con 90 mil millones de barriles de petróleo y que Venezuela salga de la OPEP Ayuda federal tardaría hasta un año por sequía y desastre federal - El Vocero Crisis de agua inunda la línea PAS - El Vocero Un momento para WindMar Home — la empresa con más de 20 años protegiendo los hogares puertorriqueños.Solar para bajar tu factura. Techo para proteger tu inversión. Agua para que nunca te quedes sin — especialmente con las sequía. Y batería para total independencia energética.Todo bajo una misma empresa. Un solo llamado. Llama al 787-489-1155 o visita windmarhome.comWindMar Home — los que se preparan hoy , duermen tranquilos mañana.#windmarhome #windmarhome #incluyeauspicioCorrección admite que no hay razón para cancelar contrato ordenado por la gobernadora cancelar y debe 112 millones a empleados en retroactivo - El Nuevo Día Tormenta Dolly sigue camino hacia acá para lunes - NHCSolX cesantea ~200 en Aguadilla tras suplidos no poder entregar materiales - Jay FEmbalses al borde: Carraízo en 37.27m, a 26 cm del nivel de "control" (37.00m); La Plata bajó 11 cm a 45.05m; 14 de 19 embalses reportaron bajas. 180,000 abonados en racionamiento de 48 horas - El Vocero Yanira Raíces incumplía requisitos desde 1999, por eso pide distinción especial - El Nuevo Día Jefe de DACO plantea correr para alcalde de Cataño y tiene comité para político mientras es secretario - El Nuevo DíaRegresa SuperPAC Democracia es Prosperidad - El Nuevo Día Norma Burgos pide break al Senado para entregar datos de los últimos días de Domenech y García Posible cirugía Tommy John para Fernando Cruz Boston Scientific sufre ciberataque global, afectó su capacidad de procesar y enviar pedidos; reportado a la SECFederación agrícola en quiebra - El Nuevo Día Trump renombra Lago Ontario "Lake America":7 de 14 unidades de respuesta rápida fuera de servicio, se las compramos a los dueños de Genera y no sirven, Negociado dice que va a investigar - El Nuevo Día Escala la pelea con Canadá, Trump impuso aranceles de 50% a una batería de productos canadienses; Canadá respondió con 50% al alambre de cobre, madera y carbón vegetal gringos, y ofreció C$504M para atraer a 64 científicos estadounidenses - Bloomberg Hoy el jefe de la FED da su primer discurso Jackson Hole a las 10 Nvidia, imparable. $60 billones de ganancia trimestral, esto es algo nunca antes visto Lilly logra que aprueben Mounjaro para condiciones cardíacas - Bloomberg Irán cumple 6 meses de guerra. Hormuz "reabre" y el crudo se estabiliza, pero el diésel en EEUU sigue a $5.65 el galón250+ negocios piden alivio de hasta $10,000 a Turismo, 254 solicitudes de las 450-500 estimadas - El Nuevo Día Trump vs. Canadá. Aranceles de 50%, Canadá responde, y Trump renombra el Lago Ontario "Lake AmericaLOS DATOS DEL DÍABrent: $87.65/barril  Diésel EEUU (retail): $5.65/galón (+19.8¢ en la semana)  ·  S&P 500: 7,730.99 (+0.7%)  ·  Dow: 53,569.44 (+0.2%)  ·  Nasdaq: 26,541.35 (+1.6%)Bono 10 años: 4.67%  ·  Euro/USD: 1.1656  ·  Gas natural (Henry Hub): ~$3.00/MMBtu (Europa en máximos de 3 años)  ·  Hipoteca 30 años: 6.66%  ·  Oro: mineras +43% en agosto

Vanessa Feltz has spent more than thirty years at the heart of British television. I built Heretics outside it. We began by agreeing that television had become sanitised. Within minutes, she was asking whether I was ashamed of myself. What follows is a collision between two very different ideas of public conversation: one prioritises care and responsibility; the other prioritises bluntness and freedom. You decide which one the future belongs to. Sub to her new show here: https://www.youtube.com/@VanessaFeltzYouTube Following the sudden end of her Channel 5 programme, Vanessa reveals how Paramount pulled the plug, why terrestrial television is losing its audience and what decades in British broadcasting taught her about censorship, controversy and the shrinking space for unscripted opinions. But the agreement doesn't last. A throwaway remark about Loose Women becomes an accusation of misogyny and ageism. Vanessa explains why she deplores my decision to interview Katie Hopkins, questions whether controversial figures deserve a platform and reveals whether she would invite Woody Allen into her home. Then, after Vanessa asks what I have said that made me unacceptable to mainstream television, the interview takes its most dramatic turn. We clash over transgender identity, pronouns, detransition, compelled speech and whether genuine compassion means affirming somebody's identity—or being willing to tell them something they do not want to hear. At one point, Vanessa calls me “nasty”. Shortly afterwards, she announces that she has lost the will to live. But the arguments are only half the story. Vanessa also speaks with startling honesty about growing up with parents who rarely expressed love, being made to feel grateful to any man who chose her and why she has never sustained a successful relationship. She opens up about the cruelty she experienced over her weight, starving and dehydrating herself before televised weigh-ins on Celebrity Fit Club, the gastric band that became embedded in her liver and why she wishes Mounjaro and Wegovy had existed before she underwent gastric bypass surgery. There are also extraordinary stories involving Madonna, Katie Price, Woody Harrelson, Jeff Goldblum, The Big Breakfast and the famous guests who behaved very strangely after climbing into bed with Vanessa. Was Vanessa defending kindness and responsibility—or the instincts that made mainstream television frightened of real conversation? Was I defending honesty and free expression—or simply being provocative for its own sake? Watch until the end and decide for yourself. The way the conversation concludes may surprise you. Subscribe to Heretics for long-form conversations in which insiders, survivors and dissidents reveal the hidden rules of powerful people and institutions—and how those rules affect you. CHAPTERS 0:00 “Are you ashamed of yourself?” 3:54 Why mainstream television is dying 7:59 One joke turns the interview against Andrew 12:32 Is offensiveness ever “just a joke”? 18:15 The parents who rarely expressed love 21:59 Why Vanessa always needed to be chosen 25:09 Why Vanessa deplores Katie Hopkins 30:48 Vanessa discovers she was voted one of Britain's worst people 35:18 How she avoided the internet until 2020 38:27 “What have you said?” The gender clash begins 42:36 What does it really mean to be a woman? 46:18 “You're just being nasty” 50:10 When “just be kind” stops being simple 55:40 The weight-loss operation that went horribly wrong 59:03 Starving herself before a televised weigh-in 1:03:21 Why one slice of cake changes everything 1:07:19 Vanessa's YouTube reinvention—and the stars in her bed #VanessaFeltz #Heretics #AndrewGold #FreeSpeech #BritishTV Learn more about your ad choices. Visit megaphone.fm/adchoices

GLP-1 medications and peptide therapy are everywhere right now, but are they simply weight loss tools, or is there more to the conversation? In this episode of the Health Detective Podcast, Michele Scarlet sits down with holistic health practitioner Laura Young to discuss GLP-1s, peptide therapy, metabolic health, food noise, inflammation, healthy aging, and the importance of building strong health foundations first. Laura shares her own experience using GLP-1 peptides after struggling with metabolic changes following pregnancy, including how reducing food noise changed her relationship with hunger and helped support her weight loss goals. They discuss: How GLP-1s work alongside nutrition, movement, sleep, and lifestyle Food noise, cravings, hunger, and metabolic health Why GLP-1s should not be viewed as a magic fix Potential GLP-1 side effects Muscle loss and the importance of strength training and protein Peptide therapy beyond weight loss Inflammation, recovery, mitochondrial health, and healthy aging Why bioindividuality matters when considering any health intervention How to become a more informed advocate for your own health Whether you're curious about Ozempic, Wegovy, Mounjaro, GLP-1 medications, peptide therapy, weight loss, insulin resistance, or longevity, this conversation explores the bigger picture behind one of the fastest-growing areas in health and wellness. CONNECT WITH LAURA lytotalwellness@gmail.com https://www.totalwellnessolutions.com MEDICAL DISCLAIMER: This podcast is for educational and informational purposes only and is not intended to provide medical advice or to diagnose, treat, cure, or prevent any disease. Discussion of medications, peptides, supplements, or other therapies does not constitute a recommendation or endorsement by Functional Diagnostic Nutrition. Always consult a qualified healthcare professional before starting, stopping, or changing any medication, peptide, supplement, or treatment.

GLP-1 medications like Ozempic, Wegovy, Mounjaro, and Zepbound are everywhere right now. Maybe you're curious about them. Maybe you're already taking one. Or maybe part of you feels like using medication would somehow be "cheating." In this episode, Dara takes a step back from the debate and looks at the bigger picture. What do GLP-1 medications actually do? Can they reduce food noise? And if they quiet your desire for food, does that mean they've resolved the reason you were turning to food in the first place? Dara shares research and perspectives from several medical and psychological professionals, including differing opinions about who may benefit most from GLP-1 medications, what happens when the medication is stopped, and how appetite suppression could potentially interact with perfectionism and rigid thinking. But this isn't a yes-or-no episode about whether you should take a GLP-1. Instead, Dara wants you to ask better questions. If the food noise disappeared tomorrow, would the rest of your life feel resolved? What would you finally believe about yourself if you reached your goal weight? And why does that belief have to wait until you lose the weight? Dara also explores the connection between emotional eating, food noise, over-hunger, and over-desire—and why understanding the why behind your eating patterns may be just as important as changing the behavior itself. In this episode, you'll learn: What GLP-1 medications actually do to appetite and food noise Why quieting food noise isn't necessarily the same as resolving its underlying cause Why doctors and researchers don't all agree about GLP-1 medications How emotional eating can be connected to suppressing or avoiding difficult emotions The difference between over-hunger and over-desire How perfectionism and all-or-nothing thinking may factor into your relationship with food The questions to ask yourself before deciding whether a GLP-1 is right for you Important: This episode is for education and personal reflection, not medical advice. Talk with your healthcare provider about whether a GLP-1 medication is appropriate for you. If you're considering a GLP-1—or you're already taking one and still wondering what's really driving your relationship with food—Dara invites you to book a free diagnosis call to explore your unique pattern. Book your call HERE. Subscribe for more episodes on emotional eating!

GLP-1 access is getting tighter just as obesity treatment is becoming more effective, more affordable, and more important to public health.In this episode of the On The Pen Podcast, Dave Knapp breaks down two of the biggest GLP-1 stories of the week: why most states are opting out of the Trump administration's new Medicaid obesity-drug coverage model, and why employers are preparing to cut GLP-1 coverage in 2027.We also dig into the growing conversation around GLP-1 microdosing after Real Housewives of Orange County star Emily Simpson described using a lower-frequency maintenance strategy after losing around 50 pounds. Could lower-dose or intermittent GLP-1 therapy eventually become a legitimate maintenance tool? Could it help lower long-term healthcare costs? And could earlier, lower-intensity treatment eventually become a form of prophylaxis against obesity-related disease?This episode covers Medicaid GLP-1 coverage, the BALANCE model, Zepbound coverage, Wegovy coverage, employer insurance changes, compounded GLP-1 access, GLP-1 microdosing, obesity maintenance, semaglutide, tirzepatide, metabolic disease prevention, obesity medicine, healthcare costs, and the future of GLP-1 treatment.If you take Ozempic, Wegovy, Mounjaro, Zepbound, compounded semaglutide, compounded tirzepatide, or simply follow the rapidly changing world of obesity medicine, this is a conversation you need to hear.Subscribe to On The Pen for breaking GLP-1 news, obesity medicine updates, access and insurance coverage news, new weight-loss drugs, clinical research, and patient advocacy.More from On The Pen: https://linktr.ee/manonthemounjaro#GLP1 #Ozempic #Wegovy #Mounjaro #Zepbound #Semaglutide #Tirzepatide #Microdosing #ObesityMedicine #WeightLoss #Medicaid #HealthInsurance #CompoundedGLP1 #Obesity #GLP1News

Who on the team is on a GLP1 medication, why they started it and how's it going? An honest discussion. See omnystudio.com/listener for privacy information.

Wat zit er in De 7 vandaag?Ozempic en vooral Mounjaro, 2 diabetesmedicijnen die ook kunnen gebruikt worden voor gewichtsverlies, vinden razendsnel meer patiënten. Wat betekent die medicatieboom voor de factuur van onze gezondheidszorg?Bitcoin schiet na weken stilstand plots boven 70.000 dollar. Wat heeft de cryptomunt opnieuw in vuur en vlam gezet?Terwijl Iran de Straat van Hormuz probeert af te knijpen, sluizen de Amerikanen er in het geheim miljoenen vaten olie door. Hoe kan dat? Host: Bert RymenProductie: Lore AllegaertSee omnystudio.com/listener for privacy information.

People often think of weight loss drugs like GLP-1 and related agonists (e.g., Wegovy and Mounjaro) as “medications”--which they are, but they work because they mimic our own natural gut hormones to lower blood sugar, slow digestion, blunt appetite, and ultimately reduce weight. In that way, they're weight health hormone replacement therapies much like estrogen and progesterone are sex hormone replacement therapies, says this week's guest best-selling dietitian Ashley Koff, RD. We dig into weight-health hormones (GLP-1, GIP, PYY, CCK) that regulate appetite and metabolism, why digestion and hydration have to be optimized before nutrition even enters the picture, and how GLP-1 medications and hormone replacement therapy can work together in perimenopause and menopause. Plus: Ashley's own story of Everesting Mount Rainier at 52.Ashley Koff, RD, is the USA Today bestselling author of Your Best Shot (HarperOne). With more than 25 years as a practitioner and educator, she's helped redefine the conversation from weight loss to weight health — a science-based framework focused on metabolic function and hormonal regulation. She's been named one of CNN's Top 100 Health Makers and "Hollywood's Leading Dietitian" by InStyle. You can learn more about her and her work at her practice, The Better Nutrition Program.FeistyFit Info: https://livefeisty.com/training/running/feistyfitfall/Join us at Feisty Fest September 18-20, 2026: https://livefeisty.com/events/feisty-fest/Women's Mechanic Camp in Tucson: https://livefeisty.com/events/bike-mechanic-school-tucson/Courses and Coaching: https://livefeisty.com/courses/Sign up for our FREE Feisty 40+ newsletter: https://livefeisty.com/newsletters/feisty-40/Follow Us on Instagram:Feisty Menopause: @feistymenopauseHit Play Not Pause Facebook Group: https://www.facebook.com/groups/807943973376099Support our Partners:Midi Health: You Deserve to Feel Great. Book your virtual visit today at https://www.joinmidi.com/Previnex: Get 15% off your order with code HITPLAY at https://www.previnex.com/ Wahoo: Use the code FEISTY2026 to get a free Headwind Smart Fan (value $300) with the purchase of a Wahoo KICKR RUN at https://shorturl.at/WVhdr

Oil Reserves taking a hit. Finally getting to the recent high profile earnings. Market Top Calls (again). ALL TIME HIGHS – Then some consolidation (then highs again). Situational Awareness Update. SpaceX Bounces… PLUS we are now on Spotify and Amazon Music/Podcasts! Click HERE for Show Notes and Links DHUnplugged is now streaming live - with listener chat. Click on link on the right sidebar. Love the Show? Then how about a Donation? PayPal.Donation.Button({ env:'production', hosted_button_id:'JJJHP2GDEJC7J', image: { src:'https://www.paypalobjects.com/en_US/i/btn/btn_donateCC_LG.gif', alt:'Donate with PayPal button', title:'PayPal - The safer, easier way to pay online!', } }).render('#donate-button'); Follow John S. Dvorak on Twitter Follow Andrew Horowitz on Twitter Warm-Up - Oil Reserves taking a hit - Getting to the recent high profile earnings - Market Top Calls (again) Markets - ALL TIME HIGHS - Then some consolidation - Lets round out earnings - Situational Awareness Update - SpaceX Bounces... Etsy - Layoffs With Better Numbers - Etsy is cutting about 220 jobs, or 12% of its workforce. - Management said the cuts were not primarily about cost savings or AI. ----- CEO Kruti Patel Goyal stated the restructuring aims to simplify the organization, remove management layers, and speed up decision-making to better compete against massive rivals like Amazon, Temu, and TikTok Shop - Q2 revenue was about $668 million and core marketplace sales improved. - Etsy also authorized another $2 billion share buyback. - Comes after selling Depop to eBay for about $1.4 billion. Polysilicon - Tariffs Plus Price Floors - U.S. policy adds a 15% tariff and minimum import prices on polysilicon and solar products. - Goal is to protect domestic production from low-cost foreign competition. - U.S. share of global polysilicon capacity fell from about 50% in 2005 to under 2% in 2024. - First Solar and T1 Energy jumped on the announcement. ---- The same playbook - rinse and repeat Chipotle - Salmonella Returns - Minnesota officials linked a salmonella outbreak to jalapenos served at Chipotle. - Chipotle removed the affected pepper supply and switched growers. - Shares fell roughly 8%-10% as investors remembered the company's earlier food-safety problems. - This is on top of the lettuce situation with Sweetgreen- look at  STOCK CHART FOR SG Michael Burry - Calling a Major Top - Michael Burry says the market may be near a "major top." - Warned of the possibility of a 1987-style market drop. - He is short names including Nvidia, Palantir, Tesla and semiconductor stocks. - Main concern is stretched valuations and crowded trades unwinding quickly. - This may be the 100th top he has called since the GFC ---- NVIDIA TURNS GPUs INTO AN ASSET CLASS - Nvidia signed preliminary agreements with Apollo, BlackRock, Blackstone, Brookfield, Goldman Sachs and KKR to mobilize more than $500 billion for AI infrastructure. - The Wall Street firms would create dedicated pools of capital to finance Nvidia-based data centers and compute infrastructure at what Nvidia calls attractive rates for customers. - Jensen Huang: “This is really the first time that technology chips have become an investable asset class.” Nvidia says the compute assets now generate revenue and can increasingly be financed like infrastructure. - Nvidia could backstop as much as 25% of individual investments on a case-by-case basis - potentially up to about $125 billion if applied across the full program. STRATEGIC PETROLEUM RESERVE BREAKS 300 MILLION - The Strategic Petroleum Reserve fell by 6.1 million barrels to 298.7 million barrels for the week ended Aug. 7 - below 300 million for the first time since January 1983. - The SPR started 2026 around 415 million barrels, meaning more than 100 million barrels have already come out this year as releases were used to offset disruptions from the Iran conflict. - The reserve's authorized storage capacity is roughly 714 million barrels, leaving current inventories at about 42% of capacity. - Oil on the rise last week Earnings and such Toyota - Big Buyback, Better Outlook - Toyota raised its annual operating-profit forecast 13%, helped by the weaker yen. - Announced a share buyback worth up to $6.3 billion. - Quarterly operating profit still fell 9%, hurt by China weakness and higher Middle East-related costs. McDonald's - Value Problem - U.S. same-store sales rose just 0.8%, below expectations and well below last year's 2.5% growth. - Management blamed weak execution of value promotions and fewer digital deals. (and probably because everyone is taking weight loss drugs - see above) - Lower-income customer traffic remains a major pressure point. - McDonald's is bringing back more digital offers and loyalty promotions to drive traffic. Eli Lilly - Weight-Loss Machine - Lilly crushed Q2 expectations as Mounjaro and Zepbound drove most of the growth. - Mounjaro sales hit $9.94 billion; Zepbound brought in $4.93 billion. - Raised 2026 revenue guidance to $85-$87 billion. - Verzenio, its major breast-cancer drug, remains one of Lilly's biggest non-obesity products. - Lilly continues widening its lead over Novo Nordisk in the obesity-drug market. Disney - Parks Keep Printing Money - Quarterly adjusted EPS rose 28% to $2.06, beating the $1.86 estimate. - Parks and experiences revenue increased 10% to nearly $10 billion. - Global park attendance grew 4%. - Disney is selling its 50% stake in A+E Networks to Hearst for an estimated $1.2 billion. Oil - OPEC Adds Barrels, Maybe - OPEC+ agreed to raise September production targets by another 188,000 barrels per day. - The increase completes the rollback of a 1.65 million-barrel-per-day supply cut dating back to 2023. (In other words - planned so not a surprise) - Actual supply remains constrained because several producers are already pumping below quota. - Any normalization around the Strait of Hormuz could suddenly make OPEC+'s additional barrels much more important. Berkshire Hathaway - Greg Abel Starts Spending - Q2 operating earnings rose 16% to about $13 billion. - Berkshire bought $23.5 billion of stocks and sold just $3.7 billion - its first quarter as a net stock buyer in 14 quarters. - Bought back $4.5 billion of Berkshire shares, versus only $235 million in Q1. - Cash dropped from roughly $380 billion to $365 billion as Abel starts putting the massive cash pile to work. - Important shift: Buffett is still chairman, but this is one of the clearest signs yet of how Greg Abel may allocate capital differently as CEO. Situational Awareness - Nearly Blows Up, Investors Want Back In - The fund lost 67% in July after leveraged AI bets collapsed and forced a major stock sale to Citadel. - Despite the blowup, Situational Awareness was still up about 80% for 2026 because of huge earlier gains. - Bloomberg says Silicon Valley investors are already asking to put more money into the fund. - Situational Awareness is currently telling prospective investors it is not accepting new capital. - The fund has also continued making large private investments even after the near-collapse. --- Most recent was a $400B ---- There is some talk that Citadel made out like a bandit on the rescue Mercedes AMG - The Car Literally Brands You - Two Mercedes AMG owners filed a class-action lawsuit claiming the metal AMG logo embedded in the seat becomes dangerously hot in the sun. - One driver says he suffered first- and second-degree burns, with a dermatologist describing the injury as "AMG inscribed." - The lawsuit wants Mercedes to cover damages and remove the metal logos from affected vehicles. - Hard to beat this one: pay AMG money and get the logo branded into your back. Europe's Drought - History Starts Popping Out - Extreme drought and low river levels are exposing things that have been underwater or hidden for decades or centuries. - In Serbia, sunken German World War II warships have reappeared in the Danube. - In Britain, dry ground revealed outlines of medieval buildings; mammoth remains and ancient structures have also surfaced elsewhere. - Serious drought story, but visually one of the strangest side effects of the summer. Golden Toilet - $6 Million Flush - The 18-carat gold toilet was ripped out of Blenheim Palace in a five-minute raid and has never been recovered - but there is a conviction. - Prosecutors used phone data, forensic evidence and planning activity to link the gang to the theft. - One defendant had cased the palace beforehand and photographed entry points; another man had already pleaded guilty and admitted helping move the stolen gold. - Prosecutors believe the 98-kilo toilet was quickly cut up or melted down and sold as gold. - So the conviction was based on evidence of the robbery and disposal - not on recovering the actual toilet. Final Follow Up SpaceX - Space Junk Smashes Into the Moon - A dead SpaceX Falcon 9 rocket stage crashed into the moon at about 5,400 mph after drifting through space since January 2025. - The roughly 4-ton, school-bus-size object kicked up a lunar dust plume that astronomers detected from Chile. - The impact was accidental - solar activity and gravity gradually pushed the abandoned rocket stage onto a collision course. - NASA and SpaceX are now discussing ways to prevent future lunar crashes as more hardware heads toward the moon. - NEED Space garbage Trucks - something we have discussed on show for years (see next) Space Garbage Trucks - This Is Becoming a Business - Astroscale is building spacecraft designed to inspect, capture and remove dead satellites and other orbital debris. - Its ADRAS-J mission demonstrated close approach and inspection of a large piece of existing space junk - a key step before actually grabbing and removing debris. - ClearSpace is developing similar debris-removal spacecraft, including missions designed to rendezvous with and capture abandoned rocket hardware. - The business model is basically orbital towing: governments and satellite operators pay to remove dangerous junk or service aging spacecraft. - With tens of thousands of tracked objects already in orbit, "space sanitation" could become a real infrastructure business.   Love the Show? Then how about a Donation? PayPal.Donation.Button({ env: 'production', hosted_button_id: 'JJJHP2GDEJC7J', image: { src: 'https://www.paypalobjects.com/en_US/i/btn/btn_donateCC_LG.gif', alt: 'Donate with PayPal button', title: 'PayPal - The safer, easier way to pay online!' } }).render('#donate-button-2'); THE CLOSEST TO THE PIN for SpaceX (SPCX) Winners will be getting great stuff like the new "OFFICIAL" DHUnplugged Shirt!   FED AND CRYPTO LIMERICKS   See this week's stock picks HERE Follow John C. Dvorak on Twitter Follow Andrew Horowitz on Twitter

Could GLP-1 medications eventually cost just $40 to $50 per month? Hims & Hers CEO Andrew Dudum thinks so, and if he's right, it could completely change access to obesity treatment in America.But getting there may depend on something most patients have never heard of: the global peptide manufacturing supply chain.In this episode of The Weekly Dose from On The Pen, Dave Knapp, Man on the Mounjaro, breaks down one of the biggest weeks in GLP-1 and obesity medicine news, including the surprising role of Chinese pharmaceutical manufacturer WuXi AppTec, which Bloomberg described as having a “GLP-1 chokehold” while U.S. policymakers wrestle with reducing America's dependence on Chinese biotechnology.We also dig into one of the strangest GLP-1 stories of the year. Amylyx Pharmaceuticals just reported positive Phase 3 results for avexitide, a GLP-1 receptor antagonist, meaning it actually BLOCKS GLP-1. The drug reduced serious hypoglycemic events by 55% in patients with post-bariatric hypoglycemia, a debilitating condition that can occur after gastric bypass surgery.Then we get personal.Online personality Clavicular recently described becoming apathetic while taking a high dose of retatrutide, renewing the conversation around GLP-1 medications, anhedonia, emotional blunting, dopamine and reward signaling. Dave has firsthand experience with anhedonia during GLP-1 treatment and previously discussed that experience as part of coverage on the Today Show.At what point does turning down food noise start turning down everything else?We also examine Serena Williams' return to professional tennis while openly using Zepbound (tirzepatide) and the growing debate over whether GLP-1 medications could ever be considered performance-enhancing drugs in professional sports.Plus, new research suggests GLP-1 medications and significant weight loss may improve testosterone levels and fertility markers in men with obesity-related low testosterone, raising important questions about metabolic health, hypogonadism and when testosterone replacement therapy may or may not be appropriate.In this episode:

What actually happens to a patient a year into real, supervised peptide therapy? In the final episode of our peptides series, Dr. Melissa Jones and host Jamie Preston close the loop on the story that opened this whole series — and get honest about what changed, what didn't, and what every provider and patient still needs to know. This episode goes beyond the science into the human side of the story: what it actually feels like when chronic pain resolves, when weight loss becomes life-changing rather than cosmetic, and when a skeptical clinician becomes one of the most passionate advocates in the building. Jamie also shares his own journey — turning 50, managing diabetes, and reaching his goal weight — as a real example of what supervised, responsible care can look like over time. In this episode, you'll hear: An update on the chronic pain patient from Episode 1 — where he is now, and what's kept his results sustainable What the actual clinical data shows about supervised BPC-157 therapy, and where its limits are Why GLP-1 success is about far more than the number on the scale — confidence, mobility, and mental health The advice Dr. Jones gives new providers who feel nervous bringing up peptides with patients The single biggest myth about peptides she wants to put to rest for good The three things every patient should understand before they ever start a peptide This is the episode that ties the whole series together — not as a sales pitch for peptides, but as a case for doing this the right way, with the right people, for the right reasons. It's the last episode in this run, but it won't be the last time we talk about this. www.YourHealth.Org

Angela Petersen: The Ingredients for Success in Redefining What Aging Can Be In This Episode: Angela's path from United States Navy nurse to doctor of nursing and Chief Clinical and Scientific Officer at InstaMed Pharmaceuticals Why decades old research discouraged women from hormone replacement, and how the science has since been refuted The link between estrogen decline and cognitive decline, including dementia risk Why cholesterol is essential for brain function, and how inflammation, not cholesterol, drives cardiovascular risk Testing follicle stimulating hormone to understand where a woman is in the menopause transition Why bioidentical hormones and testosterone matter for both women and men How semaglutide and tirzepatide, known as Ozempic and Mounjaro, work as peptides that change metabolism, insulin response, and glucose regulation InstaMed's oral dissolving strip technology for peptides supporting skin, sleep, cognitive clarity, mitochondrial activation, growth hormone production, and pain, healing, and circulation How microplastics, seed oils, and modern plumbing may be undermining hormonal health InstaMed is a Utah based, United States manufactured company built to bring transparency to a peptide market Angela describes as the wild west Why Generation X is positioned to age differently than previous generations, and what that means for work, purpose, and financial security Why glutathione and clean eating support the body's natural detoxification process against everyday environmental toxins Key Takeaways: Redefine what normal means. Subjective symptoms deserve a real answer, even when lab numbers look fine Build a foundation first. Hormone optimization and metabolic regulation are the pillars everything else is built on Stay curious about innovation. GLP one therapy and peptide science are reshaping healthy aging and longevity Prepare for a different future. Financial self reliance, entrepreneurship, and AI fluency matter more than ever after fifty Purpose does not retire. A vital, engaged, purpose driven life is possible well beyond what past generations expected Memorable Quotes: "Normal is not normal." "You don't know how bad you felt until you start feeling good." "If you're in your fifties, you should be the most educated on AI right now." Perfect for anyone navigating midlife, menopause, or a career transition who wants to redefine what growth and vitality can look like. Connect with Angela Petersen: Book, The Wellness Glitch, available on Amazon Company, InstaMed Pharmaceuticals, getinstamed.com Contact, office line and text, 385-486-4181 Connect with Julie Riga: Website, your website Social Media, your social media handles Coaching, learn more about leadership coaching and transformation Stacklist, https://stacklist.app/julieriga Subscribe to Stay On Course wherever you listen to podcasts Share this episode with someone ready to optimize their health and reclaim their purpose #stayoncourse #healthyaging #hormoneoptimization #longevity #leadershipmindse Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Ozempic, Wegovy and Mounjaro are changing the conversation around obesity and weight management. For many people, GLP-1 receptor agonists can mean less hunger, fewer cravings and relief from the constant “food noise” that can make weight loss feel impossible.But as these medicines become more mainstream, the conversation is becoming more complex. Weight loss is not automatically the same as better health - and when appetite drops, it can become harder to eat enough protein, fibre and essential micronutrients, while protecting muscle mass matters more than ever.In this episode of Vision of Health, Dr Frankie Jackson-Spence is joined by nutrition therapist Ian Marber, author of The GLP-1 Handbook, to look beyond the headlines. They explore how GLP-1 medications such as Ozempic and Mounjaro work, who they may be suitable for, the nutritional considerations during treatment, and how to use them as part of a sustainable approach to long-term health.With more than 25 years of clinical experience, including a practice on London's Harley Street, Ian brings a practical and grounded perspective to one of the biggest conversations in modern health.What You'll LearnWhat happens nutritionally when people start eating significantly less. Why protein intake and maintaining muscle mass are so important during weight loss. How rapid weight loss can affect metabolism and body composition. Why fibre, micronutrients and overall diet quality matter when taking GLP-1s. What a realistic and balanced approach to eating can look like during treatment. Why resistance training plays an important role alongside medication. What happens when people stop taking GLP-1 medications and why weight regain is common. Practical ways to help reduce the risk of rebound weight gain. What to consider before starting a GLP-1 medication. Why obesity remains such a major global health issue. How GLP-1 medications moved from diabetes treatment into mainstream weight management. Whether weight gain is really about willpower or whether biology plays a much bigger role. How these medications affect appetite and the brain's response to food. The potential health benefits beyond weight loss, including metabolic and heart health. Who these medications may be suitable for and who they may not be suitable for. GLP-1 medications can be powerful tools, but they are not the whole picture. What you eat, how you move and how you maintain muscle all matter too.The goal isn't simply to lose weight. It's to support your health and build something that lasts.Learn More About Ian Marber: Ian Marber's websiteFollow Ian on Instagram: @ianmarber_Follow Dr Frankie Jackson-Spence: @drfrankiejsAnd don't forget to follow Vision of Health on Instagram too: @visionofhealthpodIf you learnt something from this episode, share it with someone who is trying to understand GLP-1 medications such as Ozempic and Mounjaro, how they work and whether they might be right for them. Hosted on Acast. See acast.com/privacy for more information.

Rosie O'Donnell feared she had cancer after losing weight on MounjaroAdvertising Inquiries: https://redcircle.com/brandsPrivacy & Opt-Out: https://redcircle.com/privacy

En el episodio de esta semana, Karla y René platican sobre el análisis de Grupo IUSA; el aumento en las vacantes para chief of staff; Eli Lilly and Company México y el crecimiento de Mounjaro; la popularidad de Candy Crush; y los viajes de Estados Unidos a Europa.Whitepaper Off The RecordRecomendaciones:London Falling: A Mysterious Death in a Gilded City and a Family's Search for Truth (English Edition)The End of Normal: A Wife's Anguish, A Widow's New LifeThe Mysterious Art of Conducting

Howdy Hello and welcome to "Phat Love Talk"! I'm your host, Phat Love, and I'll be taking you on a journey through news and media I find interesting! TV Shows and Movies you should be watching, Sports conversations, Books I enjoyed reading and even some personal topics like my journey with weight loss on Mounjaro, Mental Health and living with Anxiety, Depression and ADHD. Be sure to check out my brother podcast, "AlphaPhenomenon Gaming Podcast", for all future gaming episodes. This ones for me, care to take a seat and listen?

Researchers at the University of Auckland are developing an obesity treatment designed to help people lose weight without suppressing appetite. Unlike other treatments such as Wegovy and Mounjaro, this would would target the body's fat-storage process and burn it in a different way. Auckland University Molecular Medicine and Pathology professor Peter Shepherd says this treatment will burn off fat faster and reduce it before it has time to 'settle in'. "Basically, what we've done is found the hormone that controls that process and we've found a way to block that with a little chemical - a little drug that you can take orally." LISTEN ABOVESee omnystudio.com/listener for privacy information.

High-dose Vitamin D fails test in treatment of advanced colon cancer—but can prevent many early cancers from metastasizing; IV Vitamin C may delay progression Myelodysplastic syndrome, pancreatic cancer; Your future drug deliveries may be via drones; How to fight age-related “anabolic resistance”; Can osteoporosis be reversed with hormone replacement therapy and resistance exercise?

What if the peptide you just ordered online isn't wrong — it's just wrong for you? In Episode 2 of our peptides series, clinical pharmacist Dr. Melissa Jones takes us inside the actual decision-making process providers use to match a peptide to a patient, and why skipping that process is how people end up wasting money, or worse, hurting themselves. Host Jamie Preston and Dr. Jones dig into the real science: what a peptide is, how peptides signal the body, and why a healthy foundation — hormones and gut health — has to come before any peptide is even considered. From there, they cover the wide menu of options (tissue repair, skin and hair, sexual health, growth hormone support, metabolic health, sleep and stress) and what it actually means to “stack” or “cycle” peptides responsibly. In this episode, you'll hear: Why there isn't — and won't be — one peptide that does it all, and what that means for how providers build a plan How stacking and cycling actually work, and where cost becomes a real factor in the decision The difference between FDA-approved peptide uses (like Tesamorelin for visceral fat) and the anecdotal dosing happening across the wellness world The real danger in reconstituting and self-dosing peptides ordered online, explained in plain terms What responsible, supervised GLP-1 (Mounjaro, Ozempic, tirzepatide) therapy looks like — and what goes wrong with compounded, unregulated versions The specific list of patients who should avoid peptides or use extra caution, and why providers need to know it cold If you've ever wondered whether a peptide could actually help you — or wondered what your provider is really weighing before saying yes — this episode gives you the real answer, not the Instagram version. www.YourHealth.Org

Wondering how much protein you actually need while taking Ozempic, Wegovy, Mounjaro, or Zepbound?You've probably heard over and over again that you need to "eat more protein" on a GLP-1—but how much do you really need? Do protein shakes count? Can you eat too much protein? And is it true that your body can only absorb 30 grams at a time?In this episode, Registered Dietitian, Certified Personal Trainer, and GLP-1 expert Gianna answers the most common questions she hears from clients about protein and GLP-1 medications. You'll learn why protein is so important during weight loss, how protein supports muscle health, common myths to stop believing, and practical strategies to help you reach your protein goals—even when your appetite is low.Whether you're just starting your GLP-1 journey or you've been taking your medication for months, this episode will help you feel more confident about nourishing your body without obsessing over numbers.In this episode, you'll learn:Why protein is one of the most important nutrients while taking a GLP-1How protein helps support muscle during weight lossHow protein needs are determined—and why there isn't one perfect number for everyoneThe biggest protein myths I hear as a Registered DietitianWhether protein shakes "count"Can your body really only absorb 30 grams of protein at a time?Easy ways to increase your protein intake when your appetite is lowMy favorite high-protein foods for breakfast, lunch, dinner, and snacksThe biggest protein mistakes I see people make on GLP-1 medicationsIf you've ever searched "How much protein should I eat on Ozempic?", "How much protein do I need on Wegovy?", or "Do I need protein shakes on a GLP-1?", this episode is for you.

Researchers are hopeful they are on the cusp of an obesity treatment that might represent a new way to lose weight. Unlike drugs such as Wegovy and Mounjaro, which suppress appetite and can result in the loss of muscle mass, this new treatment would target the body's fat-storage proceses and leave the appetite untouched. Professor Peter Shepherd, from the University of Auckland, spoke to Ingrid Hipkiss.

Our kidneys do an incredible job filtering our blood every hour of every day. Most of us have two kidneys, and each one has about a million microscopic filters called glomeruli. Unlike the filters in our HVAC system, though, these filters cannot be replaced. But they do their work so well and unobtrusively that most of us don't even think about our kidney function. Although 37 million Americans have kidney trouble, the majority are unaware of their situation. Two tests could reveal how well the kidneys are working. What are they, and how often should you ask about them? At The People's Pharmacy, we strive to bring you up‑to‑date, rigorously researched insights and conversations about health, medicine, wellness and health policies and health systems. While these conversations intend to offer insight and perspective, the content is provided solely for informational and educational purposes. Please consult your healthcare provider before making any changes to your medical care or treatment. How You Can Listen You could listen through your local public radio station or get the live stream at 7 am EST on Saturday, August 8, 2026, through your computer or smart phone (wunc.org). Here is a link so you can find which stations carry our broadcast. If you can't listen to the broadcast, you may wish to hear the podcast later. You can subscribe through your favorite podcast provider, download the mp3 using the link at the bottom of the page, or listen to the stream on this post starting on August 10, 2026. What Are the Two Tests That Reveal Kidney Trouble? Chronic conditions like high blood pressure and diabetes put a strain on the kidneys. They are very common problems that signal the need for kidney function monitoring. Our guest expert, Dr. Samir Parikh, suggests that all of us should know our numbers. One is derived from the level of creatinine in the blood. This is normally part of a basic metabolic panel. Usually, the panel results will include a number for the estimated glomerular filtration rate (EGFR) calculated from the value for blood creatinine. The other crucial test is a urine test for protein. Keeping Kidneys Healthy by Staying Properly Hydrated One of the simplest tactics to keep kidneys healthy is to provide them with enough liquid. We get some fluid from the food we eat, which may be one reason eating fruits and vegetables seems to be good for us. They are full of water! We also need to drink fluid, and plain water is probably the best choice. It would be smart to use thirst as a guideline and make sure to drink when thirsty. We do avoid overdoing water consumption, though, as overloading the kidneys with more fluid than they can handle is dangerous as well. Medicines That Are Hard on the Kidneys We mentioned to Dr. Parikh the experience of an older friend, a devoted runner, who discovered that taking ibuprofen after a run reduced the likelihood of having to get up overnight to urinate. He reminded us and our listeners that nonsteroidal anti-inflammatory drugs (NSAIDs) like ibuprofen, naproxen, celecoxib or meloxicam can be hard on the kidneys. That doesn't mean we shouldn't ever take such pain relievers, but perhaps we should try not to make it a habit. When we asked about other medicines that might be tough on the kidneys, he mentioned PPIs. Proton pump inhibitors such as omeprazole (Prilosec) or esomeprazole (Nexium) are often used to treat heartburn or other digestive symptoms. Regular use can put a strain on the kidneys, although the gastroenterologist recommending the medicine might not warn you of that side effect. We asked about environmental toxins and learned that heavy metals such as lead or arsenic can harm the kidneys along with other organs. We should make sure that the food we eat and the water we drink are not contaminated with such compounds. The Possible Benefits of Vitamin B Dr. Parikh has been studying how the kidneys respond to the B vitamin nicotinamide. The preliminary work he and his colleagues have done so far is promising. However, they have not conducted clinical trials to find out whether the vitamin could help people with early kidney disease. Because kidneys work so hard, they need a lot of energy to be produced by the mitochondria in their cells. Those mitochondria need NAD+ (nicotinamide adenine dinucleotide) to function at their best. Providing additional nicotinamide appears to help (Nature Reviews. Nephrology, Feb. 2020).  One to three grams a day appears to be safe and may be beneficial. Medications That Can Promote Kidney Health Some medicines initially developed for other conditions are proving to be helpful in treating kidney disease. In particular, these include diabetes drugs known as SGLT2 inhibitors like dapagliflozin (Farxiga) or empagliflozin (Jardiance). They help slow the decline of kidney function (New England Journal of Medicine, Nov. 4, 2022). GLP-1 agonists may also be familiar because they too are used to treat diabetes. Medications such as semaglutide (Ozempic, Rybelsus, Wegovy) and tirzepatide (Mounjaro, Zepbound) have made headlines as weight loss and diabetes meds, but they also can reduce the risk of kidney failure and other bad outcomes (Lancet. Diabetes & Endocrinology, Jan. 2025). The benefits of these types of drugs should give us hope that we can go from slowing the progression of kidney disease to stopping it in its tracks Taking Care of Your Kidneys We asked Dr. Parikh what we should be doing to care for our kidneys and keep them healthy. He urged us once again to know our numbers: most importantly, the numbers from the two tests we discussed, blood creatinine and urine protein. Other numbers that are important for kidney are our blood pressure and, for those with diabetes, HbA1c. In addition to paying attention to all those numbers, we need to embrace a lifestyle that will help keep them where they belong. That means following a heart-healthy diet, staying physically active and getting adequate sleep. This Week’s Guest Samir M. Parikh, M.D., FASN, is Professor of Internal Medicine and Pharmacology and Chair of Internal Medicine at the University of Texas Southwestern. He holds the Donald W. Seldin Distinguished Chair in Internal Medicine and the Ruth W. and Milton P. Levy, Sr., Chair in Molecular Nephrology. Dr. Samir Parikh, University of Texas Southwestern Listen to the Podcast The podcast of this program will be available Monday, August 10, 2026, after broadcast on Aug. 8. This week's podcast has additional information on a possible role for sodium bicarbonate (baking soda) for kidney function. We also discussed medical silos, and how that leads to gastroenterologists overlooking the kidney risks from PPIs. Also, what should prospective kidney donors consider? You can stream the show from this site and download the podcast for free. Download the mp3, or listen to the podcast on Apple Podcasts or Spotify.

Hoy puedes aportar tu granito de arena para ayudar a Venezuela

Could you please comment on the new study that finds protein restriction could slow aging?Considerations for protein intake across the lifespanMy bone mineral density has improved with strontium. Should I stop taking it?  What about vitamin K2?

Market update for Thursday August 6, 2026Check out the Public app for incredible investing tools and to support the show (LINK)Follow us on Instagram (@TheRundownDaily) for bonus content and instant reactions.In today's episode, Zaid covers:What the gold rally says about the dollar, bond yields and the FedDisney's earnings beat, powered by parks, streaming and Toy Story 5Eli Lilly's monster quarter as Mounjaro and Zepbound sales surgeDoorDash's DashPass growth and Sandisk's surprising post-earnings selloffWhy used electric vehicles are suddenly rising in value

Hoy puedes aportar tu granito de arena para ayudar a Venezuela

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into the intricate web of scientific advancements, regulatory updates, and strategic maneuvers shaping the industry. Let's begin with Eli Lilly's impressive financial performance, clocking a record-breaking $23 billion in revenue for Q2 2023. This achievement, driven by the success of Mounjaro and Zepbound in metabolic diseases, underscores the competitive landscape of therapies targeting chronic conditions. However, the slower launch of Foundayo highlights ongoing challenges. Meanwhile, competition in obesity treatments is intensifying as Novo Nordisk's Wegovy continues to dominate despite new entrants like Eli Lilly's Foundayo. This scenario reflects growing patient preference for oral medications over injectables. Gilead Sciences' HIV prevention franchise has exceeded $1 billion in quarterly sales, reflecting an increasing reliance on effective small molecule therapies for infectious diseases. Gilead also remains a focal point with its HIV pre-exposure prophylaxis franchise reaching sales milestones amid legal victories defending their tenofovir-based treatments. These legal precedents could influence future innovation policies across the industry. Artificial intelligence continues to make waves in drug discovery and clinical trials. Icon's partnership with Anthropic aims to integrate AI capabilities to accelerate drug development timelines. Similarly, Phylo and Chugai Pharmaceutical are collaborating to optimize drug discovery workflows using advanced AI platforms. These collaborations highlight a strategic move towards enhancing efficiency in drug development processes. In oncology, Amplia Therapeutics and Eli Lilly are evaluating a combination therapy for non-small cell lung cancer, while Evexta Bio and Roche are exploring a joint study for metastatic breast cancer. These partnerships underscore the industry's focus on combination therapies and precision medicine to improve cancer treatment outcomes. Additionally, AstraZeneca's partnership with CSPC Pharmaceutical to enhance biologics manufacturing in China signifies the importance of localized production capabilities. On the regulatory front, Arrowhead Pharmaceuticals' acquisition of an FDA rare pediatric disease priority review voucher for Plozasiran represents a commitment to addressing unmet needs in rare diseases. This voucher could expedite new drug applications, potentially bringing life-saving treatments to patients more quickly. Despite these advancements, challenges persist. Novo Nordisk's Cagrisema failed to achieve its primary endpoint in a Phase 3 trial for type 2 diabetes, highlighting the complexities of developing combination therapies for metabolic disorders. Similarly, Eli Lilly's discontinuation of its Phase 1/2 trial for GBA1 gene therapy reflects the hurdles faced in advancing gene therapies. Looking at industry dynamics, Amgen's decision to discontinue its early-stage obesity drug signifies a strategic shift towards focusing on more promising pipeline candidates like Maritide. This move aligns with broader trends prioritizing candidates with significant potential impact on patient care. Amgen's 'Repatha' is experiencing renewed interest due to positive cardiovascular risk reduction data, showcasing how robust clinical results can rejuvenate existing products. In regulatory news, Merck's 'Lipfendra' has been spotlighted by the FDA as part of its Complex New Product Validation pilot program. This positions Lipfendra as a potential game-changer in the PCSK9 inhibitor category. Lastly, financial maneuvers such as Attovia Therapeutics' $289 million IPO and Expedition Therapeutics' $115 million Series B funding highlight investor confidence in novel therapeutic areas like dermatological and respiratory treatments. The pharmaceutical landscape remains dynamic with Johnson & Johnson investing heavily in gene therapy ventures like Sail Biomedicines for CAR-T therapies. Meanwhile, regulatory challenges persist as seen with Capricor's cell therapy setback due to statistical complexities during FDA reviews. Despite setbacks faced by some companies, innovations continue to thrive. The launch of personalized genetic therapy centers signals a shift towards individualized medicine while research into safer CAR-T therapies progresses. In conclusion, these developments reflect an industry driven by innovation amidst regulatory challenges and strategic adjustments. As companies navigate this evolving landscape, their decisions will shape future healthcare innovations and patient care outcomes. Thank you for joining us on Pharma Daily; stay tuned for more insights from the world of pharmaceuticals and biotech.Support the show

P.M. Edition for Aug. 5. Seven-year-old Whatnot is gaining popularity among people drawn to its high-energy live auction sales on everything from fashion to trading cards. But as WSJ retail reporter Hanna Krueger discusses, some users say they're hooked even when they feel like they should walk away. Plus, progressive candidate Abdul El-Sayed clinched the Democratic senate nomination in a closely-watched race in Michigan. We hear from Journal reporter Terell Wright about what this means for the Democratic party's future. And Google shakes up the leadership of its AI operations as it struggles to keep pace with competitors' top models. Alex Ossola hosts. Whatnot, the Live Shopping App Where Some People Bid Until They're Broke  Sign up for the WSJ's free What's News newsletter. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Tired of ADHD strategies that don't work? Start with this training: Stop Trying to “Fix” Your ADHD. You're Not Broken: https://programs.tracyotsuka.com/sign-up_____About one in nine adults is on a GLP-1 right now. And women with ADHD kept telling me the exact same thing after starting GLP-1 medications: they expected to lose weight, but they did not expect their brains to feel different.The brain fog lifted. The food noise got quieter. Energy felt steadier. Emotional reactions became easier to interrupt. For some, inflammation, pain, bloating, cravings, and compulsive behaviors changed too.So I brought back Dr. Kalin Johnson to tell us whether there is real science behind that or whether we are getting ahead of the evidence. Kalin is a licensed clinical pharmacist, functional medicine wellness coach, and patient advocate who runs a concierge whole-person care practice for high-achieving, high-masking neurodivergent adults. She is also queer, ADHD, autistic, and living with hypermobile Ehlers-Danlos Syndrome, and this is her fourth time on the show.In this episode, Kalin and I get into how GLP-1 receptors communicate across the gut, brain, pancreas, immune system, and vagus nerve, and why that matters for ADHD women. They also talk about food noise, brain fog, inflammation, metabolic health, emotional regulation, microdosing, side effects, muscle loss, access, and what the research still cannot tell us.ResourcesWebsite: https://www.kalinjohnson.comInstagram: https://www.instagram.com/kalinpharmdLinkedIn: https://www.linkedin.com/in/kalin-johnsonpharmdAnia Jastreboff, MD - Director of the Yale Obesity Research Center, principal investigator on many of the landmark trials for tirzepatide and retatrutide. If you watch only one thing, watch her Lincoln Center talk. https://medicine.yale.edu/profile/ania-jastreboffDr. Spencer Nadolsky - https://www.instagram.com/drnadolskyRocio Salas-Whalen MD - https://www.instagram.com/drsalaswhalenSend a Message: Your Name | Email | Message Explore more from me:

On Brand with Donny Deutsch — Brands of the Week: Spider-Man's Record Opening, Vincent Pastore Tribute, Chicken Crushes Beef & AI Rental Scams Donny Deutsch and Lou Pellegrino break down the brands shaping the zeitgeist this week. Spider-Man: Brand New Day starring Tom Holland and Zendaya smashes the all-time domestic opening weekend record with a $360M debut. The team pays tribute to Vincent Pastore ("Big Pussy" from The Sopranos), who passed away at 80, with Lou sharing behind-the-scenes stories from Sirius XM's Wiseguy Show. Plus: Pepsi teams up with beauty brand Glamnetic for a body care collab; chicken prices overtake beef as grilling-season inflation hits consumers (Chick-fil-A, Wingstop, Raising Cane's win; McDonald's and Burger King struggle); Reebok relaunches in basketball with Shaquille O'Neal and Allen Iverson; a viral rescue monkey named Punch the Monkey; Ozempic and Mounjaro linked to hair loss in a new BMJ study; the protein-maxing backlash and mTOR aging research; record back-to-school spending; a Barbie 2 contract standoff with Margot Robbie, Ryan Gosling, and Greta Gerwig; AI-powered rental scams on the rise; state fair food trends going viral on TikTok; and William Shatner, 95, headlining a heavy metal band at Riot Fest. Learn more about your ad choices. Visit megaphone.fm/adchoices

Plus: Disney's third-quarter revenue was boosted by theme park visitors and Toy Story 5. And Eli Lilly posted higher revenue on continued GLP-1 demand. Alex Ossola hosts. Sign up for WSJ's free What's News newsletter. An artificial-intelligence tool assisted in the making of this episode by creating summaries that were based on Wall Street Journal reporting and reviewed and adapted by an editor. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Send us Fan MailWhat happens when God calls you to leave a comfortable life before showing you exactly where He is leading?In this episode of You Are More, I sit down with David Knapp, creator and host of On the Pen, for an honest conversation about fear, faith, purpose, and trusting God with an uncertain outcome.David's journey began after he was diagnosed with Type 2 diabetes and started taking Mounjaro. Wanting to understand the medication, he immersed himself in scientific literature, FDA documents, and emerging research about GLP-1 medications.When he realized few people were translating that complicated information into language patients could understand, he began sharing what he was learning.At the time, David was selling traffic signals and creating videos wherever he could—including inside his Ford Flex. Today, On the Pen is a top-rated podcast, and David has become one of the country's leading independent voices and patient advocates in the GLP-1 space.But this conversation is about so much more than David's professional success.We talk about the limiting belief that nearly kept him in a comfortable career, the moment he knew it was time to take a leap of faith, and how God used every part of his previous season to prepare him for what came next.David also shares what happened when he unexpectedly needed approximately $40,000 to close on a new studio—just as his largest podcast sponsor backed out. His wife and four children gathered around him to pray, and within 24 hours, every dollar they needed had been provided.This is a powerful reminder that experiencing fear does not mean we lack faith. Fear is an emotion, but cowardice is allowing fear to keep us from doing what God has asked us to do.Your fear may come with you, but it does not get to lead you.If you feel God calling you out of your comfort zone, this conversation will encourage you to remember His past faithfulness, pray bigger, take the next step, and trust Him with the outcome.In this episode, we discuss:• David's journey from Type 2 diabetes to GLP-1 advocacy• How On the Pen became a trusted podcast and platform• Leaving a comfortable career to follow God's calling• The difference between fear and cowardice• Why resistance is not always a sign to stop• Trusting God through financial and business uncertainty• The family prayer that preceded a $40,000 breakthrough• Teaching the next generation to pray big• Remembering God's faithfulness when facing a new giant• Believing that God is truly who He says He is• Using influence and opportunity for Kingdom impactConnect With Us:Website: https://www.youaremore.comJoin The 6AM Club Bible Study! Bible Study: https://www.youaremore.com/bible-study Free Download: 5 Steps to Win Through Adversity https://youaremorepodcast.com/store Social Media: Follow us on Facebook https://www.facebook.com/youaremorepodcast and Instagram https://www.instagram.com/amywienands/ Email: amy@amywienands.comCHAPTERS:00:00 Welcome and Meet David Knapp02:02 Honoring the Legacy of David's Father04:12 David's Type 2 Diabetes Diagnosis07:02 Why He Started Talking About GLP-1 Medications09:22 The Unexpected Growth of On the Pen12:06 Leaving the Comfort of a Successful Career15:10 Trusting God with an Uncertain Outcome18:34 Why God Calls Us Beyond the Familiar21:16 Knowing When It Was Time to Take the Leap24:24 How a Ten-Year Stepping Stone Prepared David27:08 Losing Funding and His Largest Podcast Sponsor30:12 A Family Prayer and a $40,000 Breakthrough33:16 Teaching His Children to Pray Big36:08 Remembering God's Faithfulness39:14 Stepping Out in Fear Instead of Cowardice42:14 Do You Believe God Is Who He Says He Is?45:18 God Created You for a Unique Purpose47:32 Take the Next Step and Watch God MoveIf this conversation encouraged you, subscribe to You Are More, leave a comment, and share it with someone who may be standing at the edge of their next step.Remember: you truly are more.Be intentional, stay focused, and remember you are more! 

Should Christians take GLP-1 medications like Ozempic, Wegovy, Zepbound, or Mounjaro? In this episode, we're diving into a biblical perspective on these increasingly popular weight-loss medications. Rather than giving a one-size-fits-all answer, we'll explore how to seek the Holy Spirit's wisdom, discern God's direction for your health journey, and ensure that Christ—not any tool—remains at the center of your confidence, healing, and identity. What You'll Learn: Why GLP-1 medications are a tool—not a savior How to discern whether a GLP-1 is right for your unique situation The difference between quieting food noise and healing your relationship with food Common risks and limitations of GLP-1 medications Questions to prayerfully ask before making a health decision How to pursue health in a way that brings glory to God Why your confidence and identity should always be rooted in Christ Ready to heal your relationship with food with Jesus at the center? Book a FREE 30-minute call with Abbie here: https://bio.site/abbiefrye

What GLP-1 drugs don't tell you, why muscle is your longevity organ, and the surprising gut-estrogen connection.In Part 2 of my conversation with integrative oncology expert Dr. Nasha Winters, we dive into one of today's hottest topics: GLP-1 medications like Ozempic and Mounjaro. We unpack why losing weight doesn't always mean becoming healthier, why muscle is truly your longevity organ, and how body composition—not just the number on the scale—can dramatically impact your future health.We also finally answer the question we left hanging in Part 1: what is the estrobolome, and why does your gut bacteria have this much control over your estrogen? Dr. Nasha breaks down how to build your body's own natural GLP-1 production, what your continuous glucose monitor can teach you that has nothing to do with food, and one seriously blunt truth about hormones and your love life that might change how you think about your next doctor's visit.This conversation is science-backed, practical, and empowering, reminding us that there are no quick fixes when it comes to longevity—just small, consistent choices that build a healthier future…plus we give the steps to get there.In This Episode You'll Learn:Why losing muscle during weight loss can shorten longevity.The surprising reason body composition matters more than the scale.What "TOFI" (thin outside, fat inside) means, and why it's more dangerous than looking overweight.How visceral fat influences hormones and toxin storage.How to build your body's own natural GLP-1, no prescription required.Why intermittent fasting isn't one-size-fits-all—and how to do it safely.How morning sunlight and meal timing support metabolic health.The surprising insights that a continuous glucose monitors can teach you about your own body.The connection between gut bacteria, estrogen metabolism, and healthy aging.Why lifestyle always outperforms supplements and quick fixes.What waking up between 1 and 3 AM might be telling you about your liver.Dr. Nasha's genuinely candid take on libido, hormones, and what's really going on.…and more!About Our Guest Expert:Dr. Nasha Winters, ND, FABNO, is an internationally recognized leader in metabolic and integrative oncology and a pioneer of terrain-centered approaches to cancer and chronic illness.Diagnosed at age 19 stage IV ovarian cancer— at a time when the average patient with her diagnosis was nearly 50 years older than she was—Dr. Winters has spent more than three decades advancing a systems-based approach to health that explores the connections between metabolism, inflammation, circadian rhythm, environmental health, immune resilience, and emotional wellbeing. She is the creator of the Terrain Ten® framework, co-author of The Metabolic Approach to Cancer and Mistletoe and the Future of Integrative Oncology, and host of the Tend the Terrain Podcast.Connect with Dr. Nasha Winters:Instagram: @drnashawintersFacebook: https://www.facebook.com/drnashaincWebsite: https://drnasha.comTerrain Ten quiz: drnasha.com/quiz___________________________________Get Cleaner, Regulated, Better Supplements for LessDid your last order of vitamins come off a big online overnight shipping platform but you have no idea how long it was sitting in an overheated warehouse?Or maybe those Omega-3's you take are actually rancid but you wouldn't know?That's why I'm excited to have found a platform that is not only efficacious and 3rd-party lab tested, but also regulated to have the ingredients in them that are on the label!And Fullscript has 100+ brands of supplements you may already be taking…only better. Safer. What your family needs.Yup — your one-stop shop for high-quality wellness and supplement products from brands people actually trust.Better still? I have been able to secure the most awesome discounts for you. Every order. Every day of the year. Even more savings with auto-ship.Whether you're leveling up your health routine, trying to stay consistent, or just attempting to remember to take your vitamins before 11 PM, Fullscript makes the whole process way easier.✨ Easy online ordering✨ Practitioner-trusted supplement brands✨ Personalized wellness support✨ Delivered straight to your door (because leaving the house is optional)Just click HERE to set up a free account. Or visit:https://us.fullscript.com/welcome/samanthaharris_store/store-start________________________________________Why wash clothes with toxic cleaners? Try this instead!It shocked me that our laundry rooms are often one of the most toxic places in our homes.After breast cancer, I began changing out my personal care and beauty but didn't even think about my cleaning supplies.For laundry, I found a few brands that are really clean and free of harmful ingredients, but still searched for that fresh scent without the toxic junk.Found it finally! Here is the link to it (and you can message me to check to see if there are any great offers happening with current savings!CLICK THIS LINK for the details and get 100 FREE LOADS

You've seen the ads. You've heard the buzz. But do you actually know what peptides are — or what they're doing inside your body? In this first episode of a three-part series, Jamie Preston sits down with Dr. Melissa Jones, a 25-year clinical pharmacist and VP at Your Health, to lay the foundation every patient and provider needs before entering the peptide conversation. Dr. Jones brings rare credibility to this space — she didn't come in as a believer, she came in as a scientist who was challenged to learn, and what she found changed how she practices. What you'll hear in this episode: Why insulin is a peptide — and why that means peptides have been in your medicine cabinet for years How BPC 157 and TB 500 work together to signal the body to heal — and the real patient stories behind that science Why GLP-1 medications like Mounjaro and Ozempic are peptides, and how they actually produce weight loss The difference between peptides and steroids (hint: one sends signals, one messes with your hormones) Why "research use only" labels are a red flag — and why compounding pharmacies matter more than you think What providers need to start asking patients right now Whether you're a patient who's been curious or a provider who's been hesitant, this episode gives you the grounded, evidence-informed starting point you've been looking for. Part two goes even deeper — but this is where it begins. www.YourHealth.Org

Can you drink alcohol while taking Ozempic, Wegovy, Mounjaro, or Zepbound?If you've been wondering whether it's safe to enjoy a glass of wine, a cocktail on vacation, or a drink at a wedding while taking a GLP-1 medication, you're not alone. This is one of the most common questions I get as a Registered Dietitian.The good news? For many people, alcohol doesn't have to be completely off-limits. But your body may respond differently than it did before starting your medication.In this episode, I'm breaking down the science behind alcohol and GLP-1 medications, why your tolerance may have changed, the risks to be aware of, and practical tips to help you make informed decisions without fear or guilt.Because living a healthy lifestyle isn't about following rigid rules—it's about understanding your body and making choices that support your goals.In this episode, we'll cover:Can you safely drink alcohol while taking Ozempic, Wegovy, Mounjaro, or Zepbound?Why alcohol may affect you differently after starting a GLP-1The latest research on GLP-1 medications and alcohol cravingsWhy dehydration and nausea deserve extra attentionHow alcohol can impact reflux and blood sugarWhat counts as one standard drinkShould you skip your GLP-1 injection if you're planning to drink?Practical tips for drinking more safely while taking a GLP-1When alcohol may not be the best choice and when to talk with your healthcare providerWhether you're planning a vacation, heading to a birthday party, or simply wondering if your Friday night glass of wine still fits into your lifestyle, this episode will help you navigate alcohol with confidence while staying focused on your long-term health.

You might think the win on a GLP-1 like Ozempic or Mounjaro is the number dropping on your scale, but I need you to ask a better question, not how much you're losing, but what kind. In some studies, 40 to 60% of the weight people lost on these drugs came from lean muscle, not fat, and that's a metabolic loss that costs you your strength and your ability to keep the weight off. These are the most powerful fat-loss tools we've ever had, but a tool without a protocol is just potential. Hit your protein and lift, or you're trading muscle for a number you'll spend years trying to earn back. CLICK HERE TO BECOME GARYS VIP!: https://bit.ly/4ai0Xwg Thank you to our partners A-GAME: “ULTIMATE15” FOR 15% OFF: http://bit.ly/4kek1ij AION: “ULTIMATE10” FOR 10% OFF: https://bit.ly/4h6KHAD AIRES: "ULTIMATE20 " FOR 20% OFF: https://bit.ly/4a3Duze BAJA GOLD: "ULTIMATE10" FOR 10% OFF: https://bit.ly/3WSBqUa BODYHEALTH: “ULTIMATE20” FOR 20% OFF: http://bit.ly/4e5IjsV COLD LIFE: THE ULTIMATE HUMAN PLUNGE: https://bit.ly/4eULUKpCYMBIOTIKA: "BRECKACYM30" FOR 30% OFF: https://bit.ly/4tjyluP GENETIC METHYLATION TEST (UK ONLY): https://bit.ly/48QJJrk GENETIC TEST (USA ONLY): ⁠https://bit.ly/3Yg1Uk9 GOPUFF: GET YOUR FAVORITE SNACK!: https://bit.ly/4obIFDC H2TABS: “ULTIMATE10” FOR 10% OFF: https://bit.ly/4hMNdgg HEALF: 10% OFF YOUR ORDER: https://bit.ly/41HJg6S PEPTUAL: “TUH10” FOR 10% OFF: https://bit.ly/4mKxgcn SNOOZE: LET'S GET TO SLEEP!: https://bit.ly/4pt1T6V WHOOP: JOIN & GET 1 FREE MONTH!: https://bit.ly/3VQ0nzW Watch  the “Ultimate Human Podcast” every Tuesday & Thursday at 9AM EST: YouTube: https://bit.ly/3RPQYX8 Podcasts: https://bit.ly/3RQftU0 Connect with Gary Brecka Instagram: https://bit.ly/3RPpnFs TikTok: https://bit.ly/4coJ8fo X: https://bit.ly/3Opc8tf Facebook: https://bit.ly/464VA1H LinkedIn: https://bit.ly/4hH7Ri2 Website: https://bit.ly/4eLDbdU Merch: https://bit.ly/4aBpOM1 Newsletter: https://bit.ly/47ejrws Ask Gary: https://bit.ly/3PEAJuG Timestamps 00:00 - Intro of Show 00:22 - Weight loss vs fat loss 00:38 - What GLP-1 does in the body 01:02 - Semaglutide: the first generation 01:28 - Tirzepatide and the dual agonist 01:45 - Retatrutide and 24.2% body weight loss 02:20 - Why each added receptor works 02:38 - The hidden cost: protecting lean muscle 03:05 - 60% of weight loss from muscle 03:35 - The two-part fix: protein and training 04:05 - Protein targets and leucine-rich sources 04:30 - Resistance training and compound lifts 05:00 - Use the medication, do the work Disclaimer: This podcast is for informational purposes only and does not provide medical advice. It is not intended for diagnosing or treating any health condition. Always consult a licensed healthcare professional before making health or wellness decisions.  Gary Brecka is the owner of Ultimate Human, LLC which operates The Ultimate Human podcast and promotes certain third-party products used by Gary Brecka in his personal health and wellness protocols and daily life and for which Ultimate Human LLC and / or Gary Brecka directly or indirectly holds an economic interest or receives compensation.  Accordingly, statements made by Gary Brecka and others (including on The Ultimate Human podcast) may be considered promotional in nature. Learn more about your ad choices. Visit megaphone.fm/adchoices

The Cutting Edge #26 Are you currently taking a GLP-1 medication (like Ozempic, Wegovy, Mounjaro, or Zepbound) and planning for plastic surgery or general anesthesia? In this critical episode of The Cutting Edge Podcast, host Mel sits down with bariatric therapist Ashlyn Douglass-Barnes and board-certified plastic surgeon Dr. Omar Beidas to unpack the medical, psychological, and surgical risks every patient must know. If you are navigating weight loss surgery, post-bariatric skin removal, or GLP-1 therapy, this video explains why stopping your injection before surgery isn't optional—it could literally save your life.

July is the Saturday of summer. Life feels a little lighter, the rules feel looser, and for a minute, you can breathe before August shows up with its deadlines, resets, and Sunday scaries.As I'm getting ready for my birthday trip and trying to soak up the last bit of that July freedom, I've been thinking about how often two things can be true at the same time. I can love the life I've worked so hard to build and still feel overwhelmed. I can be proud of how far I've come in my weight and body image journey and still have days when it feels hard. I can appreciate my body and still want change.In this episode, we're talking about letting go of the all-or-nothing thinking that tells us we have to pick one truth, and making room for the messy, complicated reality of healing, growth, and actually living your life.Irresistible Links:Show Notes

Los fármacos análogos de GLP-1 (Ozempic, Wegovy, Mounjaro...) están revolucionando el tratamiento de la obesidad y el sobrepeso, pero hay una dimensión de la que se habla muy poco: el ruido mental (food noise) y el estigma social.En este episodio analizamos:¿Qué es el ruido mental alrededor de la comida? Cómo los pensamientos intrusivos constantes afectan a la relación con la alimentación y por qué el GLP-1 apaga ese "ruido".El juicio de la sociedad: Por qué se acusa injustamente de "hacer trampa" o de "falta de voluntad" a quienes recurren al tratamiento farmacológico.El abordaje integral: Por qué la medicación no es una varita mágica y necesita ir acompañada de reeducación nutricional, ejercicio de fuerza y apoyo psicológico para ser sostenible.Un episodio necesario para romper prejuicios y entender la obesidad desde la ciencia, la empatía y la salud.Conviértete en un supporter de este podcast: https://www.spreaker.com/podcast/comiendo-con-maria-nutricion--2497272/support.

Everyone's talking about Ozempic. But almost no one tells you what it's quietly doing to your body, or how to use it without paying for it later.Justin Roethlingshoefer breaks down the long-term side effects of GLP-1 drugs like Ozempic, Wegovy, Mounjaro, and Zepbound (semaglutide and tirzepatide): the muscle and bone you lose, why people quit, what happens when you stop, and the protocol to do it right.This episode isn't anti-GLP-1. For type 2 diabetes, severe obesity, or high cardiovascular risk these drugs can be extraordinary. But in the STEP 1 trial, 40% of the weight lost was lean body mass: for every 10 pounds gone, up to 4 can be muscle.In this episode:

P.M. Edition for July 21. Recent AI models from China claim they're just as powerful as some of the most cutting-edge models from OpenAI and Anthropic. Journal reporter Amrith Ramkumar joins to discuss the latest reactions from Silicon Valley and the White House. Plus, General Motors had a strong second quarter as consumers kept buying pickup trucks and SUVs. And New Jersey says a software error led to almost 400 non-citizens voting in elections in the state since 2023. Alex Ossola hosts. Sign up for the WSJ's free What's News newsletter. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Plus: Novo Nordisk files a deceptive advertising lawsuit against Eli Lilly. And the latest Chinese AI model launches rattle expectations for the biggest AI players in the US. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Plus: Carl Icahn's company agrees to sell auto-service chain Pep Boys. And Ukraine strikes a deal with defense company BAE Systems to manufacture howitzers locally. Alex Ossola hosts. Sign up for WSJ's free What's News newsletter. An artificial-intelligence tool assisted in the making of this episode by creating summaries that were based on Wall Street Journal reporting and reviewed and adapted by an editor. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Chalene Johnson breaks down retatrutide, the peptide everyone is calling a GLP-3 and an Ozempic killer, cutting through the hype to get to what the science actually says. Eli Lilly's own clinical trials show weight loss results that beat anything semaglutide or tirzepatide has produced, but retatrutide is not FDA approved and is not legally available at any US pharmacy, which means almost nobody buying it online is actually getting the real thing. Chalene explains what retatrutide actually is (a triple agonist that adds glucagon receptor activity to the GLP-1 and GIP receptors already targeted by Ozempic, Wegovy, Mounjaro, and Zepbound), walks through what the phase three trial data really shows versus how it is being exaggerated online, and shares why an independent lab test of vials sold through TikTok, med spas, and Reddit found most contained only 7 to 14 percent of anything resembling the real molecule. She also unpacks the muscle preservation claims that are not backed by human data, the anhedonia and placebo effect reports circulating online, why bariatric surgery comparisons need context, and how to find a reputable source like Midi Health for anyone considering a GLP-1 through legitimate medical channels. Topics discussed: retatrutide, Ozempic, semaglutide, Wegovy, tirzepatide, Mounjaro, Zepbound, GLP-1, GLP-3, Eli Lilly, bariatric surgery, Midi Health, anhedonia, muscle wasting, peptides, BPC 157 Go Beyond The Podcast Join Chalene on her private podcast